Somatostatin receptor subtype 1 might be a predictor of better response to therapy in medullary thyroid carcinoma

The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors

Herbert Chen, Rebecca S. Sippel, M. Sue O’Dorisio et al. · Pancreas · 2010 · 580 citations · Full text

Endocrine Oncology, Surgical Oncology, Endocrine Disease +13

Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR

Giselle Fernandes Taboada, Raúl M. Luque, Leonardo Vieira Neto et al. · European Journal of Endocrinology · 2008 · 170 citations

Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid

Mauro Papotti, Ujendra Kumar, Marco Volante et al. · Clinical Endocrinology · 2001 · 134 citations

A Population‐Based Analysis of Survival Factors in Differentiated and Medullary Thyroid Carcinoma

Neil Bhattacharyya · Otolaryngology · 2003 · 123 citations

Response to Initial Therapy Predicts Clinical Outcomes in Medullary Thyroid Cancer

Susan C. Lindsey, Ian Ganly, Frank L. Palmer et al. · Thyroid · 2014 · 94 citations